Literature DB >> 15360004

Expression of HOXA genes in patients with multiple myeloma.

Heidi Rye Hudlebusch1, Marianne Lodahl, Hans E Johnsen, Thomas Rasmussen.   

Abstract

Multiple Myeloma (MM) is an incurable B-cell malignancy characterized by uncontrolled growth of plasma cells (PCs) in the bone marrow. The pathogenesis of MM is complex and still not fully understood. The HOX genes encode a family of homeodomain containing transcription factors which are crucial for embryonic development and differentiation. The HOX genes are also involved in hematopoiesis and have been shown to be dysregulated in leukemia suggesting a role in leukemogenesis. We hypothesized that expression of the HOX genes might also be of importance in MM. We screened FACS-sorted malignant PCs from a panel of 32 MM patients for the expression of HOXA 2, 3, 4, 7, 9, 10, and 11 genes by RT-PCR assays specific for each gene. We found that 9.4% (3/32) of the MM patients expressed the tested HOX genes in their PCs suggesting that HOXA genes are frequently dysregulated and might have an oncogenic potential in MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15360004     DOI: 10.1080/10428190310001625836

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia.

Authors:  Isolde Riede
Journal:  J Altern Complement Med       Date:  2010-10       Impact factor: 2.579

2.  Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells.

Authors:  T R Daniels; I I Neacato; J A Rodríguez; H S Pandha; R Morgan; M L Penichet
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

3.  Expression Landscape and Functional Roles of HOXA4 and HOXA5 in Lung Adenocarcinoma.

Authors:  Li Gao; Rong-Quan He; Zhi-Guang Huang; Guo-Sheng Li; Jiang-Hui Zeng; Jia-Yin Hou; Jia-Yuan Luo; Yi-Wu Dang; Hua-Fu Zhou; Jin-Liang Kong; Da-Ping Yang; Zhen-Bo Feng; Gang Chen
Journal:  Int J Med Sci       Date:  2022-03-06       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.